We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4118:TSEKaneka Corporation Analysis

Data as of 2026-06-26 - not real-time

¥5,775.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Kaneka’s share price is trading comfortably above its short‑term and long‑term moving averages, confirming a bullish price trend despite a recent pullback signal from the MACD histogram turning negative.
The momentum indicator sits in overbought territory, suggesting short‑term price pressure may build, while the low beta underscores a defensive profile relative to the market.
Fundamental metrics paint a value‑oriented picture: the price‑to‑earnings multiple is modest, the price‑to‑book ratio is well below one, and the dividend yield is notably high, all of which point to an attractive income stream.
A discounted cash‑flow model places the fair value above the current market price, indicating upside potential, and the company’s cash flow remains solid enough to sustain its dividend payout.
However, the sector’s cyclicality and regulatory environment for specialty chemicals introduce medium‑level risks, and the elevated 30‑day volatility suggests price swings may be sharper than the low beta would imply.
Overall, the stock appears undervalued with a strong dividend foundation, making it a compelling candidate for investors with a medium to long horizon, while short‑term traders may adopt a cautious stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near recent resistance level
  • RSI in overbought territory
  • Bearish MACD divergence

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF valuation indicates upside
  • Attractive dividend yield with sustainable payout
  • Low beta and stable cash flow

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Consistent value metrics (low P/E, low P/B)
  • Strong dividend track record
  • Strategic positioning in specialty chemicals with growth potential

Key Metrics & Analysis

Financial Health

Revenue Growth4.50%
Profit Margin3.82%
P/E Ratio11.6
ROE6.43%
ROA2.10%
Debt/Equity44.34
P/B Ratio0.7
Op. Cash Flow¥50.1B
Free Cash Flow¥-2630749952

Technical Analysis

TrendBullish
RSI62.6
Support¥5,336.00
Resistance¥5,873.00
MA 20¥5,626.35
MA 50¥5,314.16
MA 200¥4,739.82
MACDBearish
VolumeStable
Fear & Greed Index85.45

Valuation

Fair Value¥6,416.71
Target Price¥4,966.67
Upside/Downside-14.00%
GradeUndervalued
TypeValue
Dividend Yield3.64%

Risk Assessment

Beta0.35
Volatility25.10%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.